The Moses H. Cone Memorial Hospital
- Type
- Teaching hospital
- Where
- GREENSBORO, NC
- Medicare CCN
- 340091
- Received
- $808,954 in 181 records, 2025 ($91,525 general, $717,429 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit: MOSES H CONE MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 61 | $91,525 |
| 2025 | Research payment | 120 | $717,429 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Edwards Lifesciences Corporation | 8 | $156,826 | 2025 |
| Amgen Inc. | 4 | $144,506 | 2025 |
| Ionis Pharmaceuticals, Inc. | 10 | $102,797 | 2025 |
| Medtronic, Inc. | 13 | $101,797 | 2025 |
| Gilead Sciences, Inc. | 20 | $52,142 | 2025 |
| Insulet Corporation | 29 | $48,975 | 2025 |
| Janssen Research & Development, LLC | 11 | $43,493 | 2025 |
| Abbott Laboratories | 24 | $34,415 | 2025 |
| HEARTFLOW, INC. | 12 | $22,600 | 2025 |
| Alnylam Pharmaceuticals Inc. | 7 | $21,588 | 2025 |
| ABBVIE INC. | 1 | $18,000 | 2025 |
| E.R. Squibb & Sons, L.L.C. | 2 | $15,760 | 2025 |
| CVRx, Inc. | 5 | $15,162 | 2025 |
| Novartis Pharmaceuticals Corporation | 1 | $10,750 | 2025 |
| PFIZER INC. | 22 | $7,882 | 2025 |
| Neurocrine BioSciences, Inc. | 1 | $3,000 | 2025 |
| Novo Nordisk Inc | 1 | $2,500 | 2025 |
| Tandem Diabetes Care, Inc. | 5 | $1,800 | 2025 |
| Immunocore Limited | 1 | $1,700 | 2025 |
| Merck Sharp & Dohme LLC | 1 | $1,700 | 2025 |
| Genentech USA, Inc. | 1 | $1,000 | 2025 |
| AstraZeneca UK Limited | 1 | $446 | 2025 |
| Siemens Medical Solutions USA, Inc. | 1 | $111 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 120 | $717,429 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 34 | $50,775 |
| Long term medical supply or device loan | 19 | $28,044 |
| Space rental or facility fees (teaching hospital only) | 7 | $12,595 |
| Debt forgiveness | 1 | $111 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $111 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-23 | CVRx, Inc. | $1,375 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-12-22 | Medtronic, Inc. | $43,927 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | Prevail Global | 2025 |
| 2025-12-18 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-18 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-17 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-12-15 | Janssen Research & Development, LLC | $8,522 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-12-11 | Edwards Lifesciences Corporation | $4,664 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-12-09 | Gilead Sciences, Inc. | $1,605 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-12-09 | Alnylam Pharmaceuticals Inc. | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-12-05 | Edwards Lifesciences Corporation | $26,577 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-12-04 | Abbott Laboratories | $3,078 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-12-04 | Abbott Laboratories | $342 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-12-01 | Alnylam Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 | |
| 2025-12-01 | Alnylam Pharmaceuticals Inc. | $1,800 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 | |
| 2025-12-01 | Alnylam Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 | |
| 2025-12-01 | Alnylam Pharmaceuticals Inc. | $521 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 | |
| 2025-11-25 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-11-24 | Ionis Pharmaceuticals, Inc. | $49,678 | Research payment | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | IS354CS9 | 2025 |
| 2025-11-24 | Ionis Pharmaceuticals, Inc. | $3,060 | Research payment | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | IS354CS9 | 2025 |
| 2025-11-24 | Ionis Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | IS354CS9 | 2025 |
| 2025-11-24 | Ionis Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | IS354CS9 | 2025 |
| 2025-11-24 | Ionis Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | IS354CS9 | 2025 |
| 2025-11-24 | Abbott Laboratories | $414 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | NCT03309332--AMPLATZER PFO Occluder Post Approval Study | 2025 |
| 2025-11-24 | Ionis Pharmaceuticals, Inc. | $262 | Research payment | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | IS354CS5 | 2025 |
| 2025-11-21 | Janssen Research & Development, LLC | $3,044 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-11-12 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-11-10 | Abbott Laboratories | $2,736 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-11-05 | Medtronic, Inc. | $16,250 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-11-05 | Medtronic, Inc. | $5,000 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-11-05 | Insulet Corporation | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-11-05 | Medtronic, Inc. | $450 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-10-31 | Ionis Pharmaceuticals, Inc. | $20,809 | Research payment | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | IS354CS9 | 2025 |
| 2025-10-29 | Ionis Pharmaceuticals, Inc. | $10,885 | Research payment | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | IS354CS15 | 2025 |
| 2025-10-28 | CVRx, Inc. | $1,400 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-10-28 | Gilead Sciences, Inc. | $730 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-10-24 | Medtronic, Inc. | $2,400 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-10-24 | Medtronic, Inc. | $312 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-10-23 | Medtronic, Inc. | $2,390 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-10-22 | Janssen Research & Development, LLC | $4,355 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-10-22 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-21 | Gilead Sciences, Inc. | $1,920 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-10-17 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-10-17 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-10-16 | HEARTFLOW, INC. | $1,800 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-10-16 | HEARTFLOW, INC. | $1,600 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-10-15 | Edwards Lifesciences Corporation | $15,971 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-10-14 | Gilead Sciences, Inc. | $1,120 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-10-14 | HEARTFLOW, INC. | $1,000 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-10-14 | HEARTFLOW, INC. | $800 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-10-06 | Abbott Laboratories | $4,104 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-10-06 | Medtronic, Inc. | $269 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-10-02 | Edwards Lifesciences Corporation | $16,510 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-10-02 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-10-02 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-10-02 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-09-23 | Gilead Sciences, Inc. | $6,650 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-09-23 | Gilead Sciences, Inc. | $1,794 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-09-19 | Janssen Research & Development, LLC | $3,069 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-09-15 | Edwards Lifesciences Corporation | $22,618 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-09-10 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-09 | Gilead Sciences, Inc. | $900 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-09-03 | Insulet Corporation | $925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-02 | Medtronic, Inc. | $5,006 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-08-26 | Neurocrine BioSciences, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-26 | Amgen Inc. | $2,871 | Research payment | Cash or cash equivalent | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiov | 2025 | |
| 2025-08-25 | Janssen Research & Development, LLC | $2,312 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-08-22 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-08-22 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-08-22 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-08-22 | Abbott Laboratories | $684 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-08-22 | Abbott Laboratories | $684 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-08-20 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-08-20 | AstraZeneca UK Limited | $446 | Research payment | Cash or cash equivalent | Truqap Drug, Oncology | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo F | 2025 |
| 2025-08-20 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-08-19 | Gilead Sciences, Inc. | $1,920 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-08-13 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-08-11 | Abbott Laboratories | $883 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | NCT03309332--AMPLATZER PFO Occluder Post Approval Study | 2025 |
| 2025-08-06 | Ionis Pharmaceuticals, Inc. | $14,063 | Research payment | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | IS354CS15 | 2025 |
| 2025-08-06 | Ionis Pharmaceuticals, Inc. | $1,039 | Research payment | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | IS354CS9 | 2025 |
| 2025-08-01 | Medtronic, Inc. | $13,000 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | Prevail Global | 2025 |
| 2025-07-31 | Edwards Lifesciences Corporation | $5,392 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-07-29 | CVRx, Inc. | $1,375 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-07-25 | Edwards Lifesciences Corporation | $17,982 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-07-23 | Janssen Research & Development, LLC | $4,635 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-07-22 | Gilead Sciences, Inc. | $8,148 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-07-22 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-07-20 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-07-20 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-07-16 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-07-15 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-07-09 | Medtronic, Inc. | $4,908 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-07-07 | HEARTFLOW, INC. | $800 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-07-07 | HEARTFLOW, INC. | $800 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-07-01 | Insulet Corporation | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-06-25 | Amgen Inc. | $9,830 | Research payment | Cash or cash equivalent | The African American Heart Study: A Real-World Data Study of Atherosclerotic Cardiovascular Risk in African American and | 2025 | |
| 2025-06-24 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-06-23 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-06-20 | Janssen Research & Development, LLC | $3,942 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-06-10 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-06-09 | E.R. Squibb & Sons, L.L.C. | $14,060 | Research payment | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | Shared Decision Support Intervention in the Use of Cardiac Myosin Inhibition- A Pilot Program | 2025 |
| 2025-06-05 | HEARTFLOW, INC. | $2,600 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-06-04 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-06-04 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-05-30 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-05-30 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-05-30 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-05-30 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-05-30 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-05-30 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-05-30 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-05-30 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-05-30 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-05-27 | HEARTFLOW, INC. | $2,600 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-05-27 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-05-21 | Abbott Laboratories | $924 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | NCT03309332--AMPLATZER PFO Occluder Post Approval Study | 2025 |
| 2025-05-20 | Gilead Sciences, Inc. | $2,388 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-05-20 | Gilead Sciences, Inc. | $925 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-05-20 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-05-16 | Janssen Research & Development, LLC | $1,226 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-05-14 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-05-13 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-05-06 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-05-02 | Merck Sharp & Dohme LLC | $1,700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-05-02 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-05-01 | Edwards Lifesciences Corporation | $47,109 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-05-01 | CVRx, Inc. | $1,362 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-04-29 | HEARTFLOW, INC. | $2,600 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-04-29 | HEARTFLOW, INC. | $2,600 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-04-29 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-04-24 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-04-23 | Janssen Research & Development, LLC | $5,038 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-04-22 | Gilead Sciences, Inc. | $7,402 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-04-22 | Insulet Corporation | $375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-04-16 | Alnylam Pharmaceuticals Inc. | $992 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 | |
| 2025-04-15 | Gilead Sciences, Inc. | $950 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-04-11 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-04-10 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-04-08 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-04-03 | Novartis Pharmaceuticals Corporation | $10,750 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A randomized, controlled, multicenter, open-label trial comparing a post-discharge care pathway involving aggressive LDL | 2025 |
| 2025-04-01 | Gilead Sciences, Inc. | $500 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-03-31 | Medtronic, Inc. | $1 | Research payment | In-kind items and services | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-03-28 | Genentech USA, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xolair Biological, Immunology | 2025 | |
| 2025-03-25 | Medtronic, Inc. | $7,884 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2025 |
| 2025-03-18 | Gilead Sciences, Inc. | $1,310 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-03-17 | Janssen Research & Development, LLC | $1,716 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-03-12 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-03-12 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-03-12 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-03-07 | ABBVIE INC. | $18,000 | Research payment | Cash or cash equivalent | M23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination | 2025 | |
| 2025-03-04 | Gilead Sciences, Inc. | $700 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-03-03 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-02-25 | E.R. Squibb & Sons, L.L.C. | $1,700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-02-21 | Alnylam Pharmaceuticals Inc. | $14,279 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 | |
| 2025-02-19 | Gilead Sciences, Inc. | $3,310 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-02-19 | Immunocore Limited | $1,700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KIMMTRAK Drug, Oncology | 2025 | |
| 2025-02-17 | Abbott Laboratories | $3,650 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | NCT03309332--AMPLATZER PFO Occluder Post Approval Study | 2025 |
| 2025-02-14 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | NCT03309332--AMPLATZER PFO Occluder Post Approval Study | 2025 |
| 2025-02-13 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-02-13 | Abbott Laboratories | $1,368 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-02-07 | HEARTFLOW, INC. | $2,000 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
| 2025-02-05 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-01-30 | Amgen Inc. | $11,828 | Research payment | Cash or cash equivalent | REPATHA Biological, Cardiovascular | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiova | 2025 |
| 2025-01-30 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-01-30 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-01-29 | Insulet Corporation | $18,525 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-01-29 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-01-29 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-01-28 | Gilead Sciences, Inc. | $950 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-01-27 | Novo Nordisk Inc | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-01-23 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-01-22 | Gilead Sciences, Inc. | $7,470 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-01-22 | Janssen Research & Development, LLC | $5,634 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-01-16 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-01-16 | Abbott Laboratories | $684 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-01-16 | Abbott Laboratories | $684 | Long term medical supply or device loan | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-01-15 | CVRx, Inc. | $9,650 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-01-14 | Amgen Inc. | $119,976 | Research payment | In-kind items and services | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascu | 2025 | |
| 2025-01-08 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-01-07 | Gilead Sciences, Inc. | $1,450 | Research payment | Cash or cash equivalent | Yeztugo Drug, HIV | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2025 |
| 2025-01-03 | HEARTFLOW, INC. | $3,400 | Research payment | Cash or cash equivalent | FFRct Device, Coronary | 459 DECIDE Registry | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Greensboro, NC, county Guilford County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Greensboro, NC | County Guilford County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 301,198 | 547,940 | 10,730,404 |
| Population, 2020 census P1 | 299,035 | 541,299 | 10,439,388 |
| Median age B01002 | 34.3 | 37.5 | 39.1 |
| Under 18 B01001 | 21.7% | 22.0% | 21.8% |
| 65 and over B01001 | 14.4% | 15.9% | 17.2% |
| Households B11001 | 123,984 | 219,718 | 4,282,345 |
| Foreign born B05002 | 12.7% | 11.8% | 9.1% |
| Median household income B19013 | $61,515 | $68,642 | $72,388 |
| Median family income B19113 | $80,585 | $88,156 | $90,290 |
| Per capita income B19301 | $37,531 | $39,376 | $41,385 |
| Poverty rate B17001 | 17.0% | 14.6% | 13.0% |
| Unemployment rate B23025 | 5.1% | 4.6% | 4.7% |
| Civilian labor force B23025 | 158,568 | 282,362 | 5,336,863 |
| Mean commute (minutes) B08013 | 21.7 | 22.0 | 25.1 |
| Bachelor's degree or higher B15003 | 41.0% | 39.0% | 35.7% |
| Housing units B25001 | 135,665 | 238,032 | 4,895,668 |
| Owner-occupied B25003 | 50.5% | 59.9% | 66.6% |
| Renters B25003 | 49.5% | 40.1% | 33.4% |
| Median home value B25077 | $244,800 | $259,900 | $288,900 |
| Median gross rent B25064 | $1,172 | $1,163 | $1,228 |
| White, not Hispanic B03002 | 38.1% | 46.0% | 60.0% |
| Black B03002 | 41.0% | 33.5% | 20.0% |
| Hispanic or Latino B03002 | 10.5% | 10.1% | 11.3% |
| Asian B03002 | 5.2% | 5.4% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greensboro, NC.
Comments